BIO Relative Valuation
BIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BIO is overvalued; if below, it's undervalued.
Historical Valuation
Bio Rad Laboratories Inc (BIO) is now in the Fair zone, suggesting that its current forward PE ratio of 30.42 is considered Fairly compared with the five-year average of 36.20. The fair price of Bio Rad Laboratories Inc (BIO) is between 256.65 to 449.20 according to relative valuation methord.
Relative Value
Fair Zone
256.65-449.20
Current Price：320.06
Fair
30.42
PE
1Y
3Y
5Y
Trailing
Forward
17.86
EV/EBITDA
Bio Rad Laboratories Inc. (BIO) has a current EV/EBITDA of 17.86. The 5-year average EV/EBITDA is 22.39. The thresholds are as follows: Strongly Undervalued below 8.09, Undervalued between 8.09 and 15.24, Fairly Valued between 29.53 and 15.24, Overvalued between 29.53 and 36.68, and Strongly Overvalued above 36.68. The current Forward EV/EBITDA of 17.86 falls within the Historic Trend Line -Fairly Valued range.
25.96
EV/EBIT
Bio Rad Laboratories Inc. (BIO) has a current EV/EBIT of 25.96. The 5-year average EV/EBIT is 29.00. The thresholds are as follows: Strongly Undervalued below 11.90, Undervalued between 11.90 and 20.45, Fairly Valued between 37.55 and 20.45, Overvalued between 37.55 and 46.10, and Strongly Overvalued above 46.10. The current Forward EV/EBIT of 25.96 falls within the Historic Trend Line -Fairly Valued range.
3.25
PS
Bio Rad Laboratories Inc. (BIO) has a current PS of 3.25. The 5-year average PS is 4.69. The thresholds are as follows: Strongly Undervalued below 1.32, Undervalued between 1.32 and 3.00, Fairly Valued between 6.37 and 3.00, Overvalued between 6.37 and 8.06, and Strongly Overvalued above 8.06. The current Forward PS of 3.25 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Bio Rad Laboratories Inc. (BIO) has a current P/OCF of 0.00. The 5-year average P/OCF is 20.22. The thresholds are as follows: Strongly Undervalued below -7.29, Undervalued between -7.29 and 6.46, Fairly Valued between 33.98 and 6.46, Overvalued between 33.98 and 47.73, and Strongly Overvalued above 47.73. The current Forward P/OCF of 0.00 falls within the Undervalued range.
0.00
P/FCF
Bio Rad Laboratories Inc. (BIO) has a current P/FCF of 0.00. The 5-year average P/FCF is 27.06. The thresholds are as follows: Strongly Undervalued below -9.01, Undervalued between -9.01 and 9.02, Fairly Valued between 45.09 and 9.02, Overvalued between 45.09 and 63.12, and Strongly Overvalued above 63.12. The current Forward P/FCF of 0.00 falls within the Undervalued range.
Bio Rad Laboratories Inc (BIO) has a current Price-to-Book (P/B) ratio of 1.28. Compared to its 3-year average P/B ratio of 1.19 , the current P/B ratio is approximately 7.60% higher. Relative to its 5-year average P/B ratio of 1.36, the current P/B ratio is about -6.00% higher. Bio Rad Laboratories Inc (BIO) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 2.56%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 2.60% , the current FCF yield is about -100.00% lower.
1.28
P/B
Median3y
1.19
Median5y
1.36
3.92
FCF Yield
Median3y
2.56
Median5y
2.60
Competitors Valuation Multiple
The average P/S ratio for BIO's competitors is , providing a benchmark for relative valuation. Bio Rad Laboratories Inc Corp (BIO) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 0.50%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BIO decreased by 2.57% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -5.23 to -13.03.
The secondary factor is the Revenue Growth, contributed 0.50%to the performance.
Overall, the performance of BIO in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Bio Rad Laboratories Inc (BIO) currently overvalued or undervalued?
What is Bio Rad Laboratories Inc (BIO) fair value?
How does BIO's valuation metrics compare to the industry average?
What is the current P/B ratio for Bio Rad Laboratories Inc (BIO) as of Dec 05 2025?
What is the current FCF Yield for Bio Rad Laboratories Inc (BIO) as of Dec 05 2025?
What is the current Forward P/E ratio for Bio Rad Laboratories Inc (BIO) as of Dec 05 2025?